Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NCT01639001 ·Status: COMPLETED ·Phase: PHASE3

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021 ·Status: COMPLETED ·Phase: PHASE2

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT04632758 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

NCT04009317 ·Status: UNKNOWN ·Phase: PHASE3

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT02040870 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

NCT03672643 ·Status: TERMINATED ·Phase: PHASE4

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

NCT05991895 ·Status: RECRUITING

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

NCT01121588 ·Status: TERMINATED ·Phase: PHASE1

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429 ·Status: COMPLETED

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869 ·Status: RECRUITING

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02838420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT04056572 ·Status: UNKNOWN ·Phase: PHASE2

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

NCT05020457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

NCT05721950 ·Status: ACTIVE_NOT_RECRUITING

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

NCT04647110 ·Status: COMPLETED

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 ·Status: COMPLETED

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

NCT02075840 ·Status: COMPLETED ·Phase: PHASE3

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

NCT06951464 ·Status: RECRUITING ·Phase: PHASE2

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

NCT05209256 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

NCT06569420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3